An active androgen receptor (AR) is required in CRPC. Post-translational modification plays an important role in AR activation and, ultimately, in the subset of genes targeted for transcription.

Androgen receptor (AR) signaling is the primary driver of prostate ... While castration negates AR signaling for a period of time, castration resistant prostate cancer (CRPC) emerges due to ...

Announcing a new publication for Acta Materia Medica journal. Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men.

Announcing a new publication for Acta Materia Medica journal. Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men.

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

Co. Ltd. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety coupled to an androgen receptor targeting moiety through a linker acting as androgen ...

The optimistic assessment of the revenue potential for androgen receptor inhibitor Nubeqa (darolutamide ... castration-resistant prostate cancer (CRPC), but expansion into hormone-sensitive ...